Ash 2022 preview – a new multiple myeloma mechanism makes a splash

Ash 2022 preview – a new multiple myeloma mechanism makes a splash

Source: 
EP Vantage
snippet: 

The appearance of Johnson & Johnson’s talquetamab in this year’s Ash press programme will highlight GPRC5D blockade as an important new mechanism in treating multiple myeloma.